14.85 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||14.80 - 15.25|
|52 Week Range||10.00 - 19.19|
|Beta (3Y Monthly)||-0.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.60|
Oxford Immunotec Global PLC (OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Select kit by the China Food and Drug Administration (CFDA). With the T-Cell Select kit, blood samples collected in a single standard blood tube can be stored for up to 54 hours at room temperature before use, further extending the company’s unrivaled simplicity and logistics advantages for customers. Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease.
Oxford Immunotec Global PLC’s (NASDAQ:OXFD): Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. With the latest financial year loss of Read More...
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -140.00% and -52.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Abingdon, Britain-based company said it had a loss of 13 cents per share. Losses, adjusted to account for discontinued operations, were 24 cents per share. The results fell short of Wall Street expectations. ...
Closed transformative deal to sell U.S. laboratory services business to Quest DiagnosticsT-SPOT®.TB tests sold in the third quarter exceeded one million tests for the first.
SECAUCUS, N.J. and OXFORD, England and MARLBOROUGH, Mass., Nov. 6, 2018 /PRNewswire/ -- Quest Diagnostics (DGX) and Oxford Immunotec Global PLC (OXFD) today announced that Quest Diagnostics has completed its previously announced acquisition of the U.S. laboratory services business of Oxford Immunotec. The T-SPOT.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest Diagnostics' portfolio of innovative infectious disease testing services. As part of the transaction, Oxford Immunotec will sell T-SPOT.TB test kits and related accessories to Quest Diagnostics under the terms of a long-term supply agreement.
Zacks.com highlights: General Finance, Northern Oil and Gas, American Outdoor Brands, Amber Road and Oxford Immunotec Global
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Amarin Corporation ...
The acquisition, once completed, will include the T-SPOT®.TB tuberculosis and the Accutix™ tick-borne disease testing services provided by Oxford Immunotec's laboratories in Memphis, TN, and Norwood, MA. As part of the transaction, Oxford Immunotec will sell T-SPOT.TB test kits and related accessories to Quest Diagnostics under the terms of a long-term supply agreement, which would be effective at closing of the acquisition.
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -4.17% and 2.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Abingdon, Britain-based company said it had a loss of 25 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Oxford Immunotec Global PLC (NASDAQ: OXFD ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 8:00 AM Eastern ...
Oxford Immunotec Global PLC (OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company`s results at 8:00 a.m. Eastern Time the same day. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time.